1. Medicines
  2. Respiratory and Inflammation
  3. ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder)

Prescribing information

 

ATECTURA® BREEZHALER® (indacaterol acetate/mometasone furoate inhalation powder)

__________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

ATECTURA BREEZHALER is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short-acting beta2-agonists.1

 

Reference

  1. ATECTURA BREEZHALER Summary of Product Characteristics.
ATE20-C001 November 2020.
Respiratory and Inflammation
Print
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]